(IN BRIEF) Sanofi and Regeneron have received European Commission approval for Dupixent to treat children aged two to 11 with chronic spontaneous urticaria, marking the first targeted therapy available for this condition in young patients. Supported by data from the … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Alyssa Johnsen, biologics, chronic spontaneous urticaria, clinical trials, CSU, CUPIDKids, dupilumab, Dupixent, EU approval, European Commission, George D. Yancopoulos, immunology, LIBERTY CUPID, pediatric dermatology, pediatric treatment, Regeneron Pharmaceuticals, Sanofi, Sanofi and Regeneron Advance Pediatric Care with EU Approval of Dupixent for Chronic Spontaneous Urticaria, type 2 inflammation
(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged 1 to 11 years, weighing at least 15 kg, who suffer from eosinophilic esophagitis (EoE). Dupixent is now the first … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged dupilumab, Dupixent, Eosinophilic Esophagitis (EoE) Treatment, FDA approval, George D. Yancopoulos, Naimish Patel, pediatric, Regeneron, Sanofi
(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release
Posted in Business, Education, France, Healthcare, Management, News, Pharma & Biotech, Science, Technology
Tagged COPD, Dupixent, Exacerbations, George D. Yancopoulos, Naimish Patel, NOTUS, Regeneron, Sanofi
Dupixent ist das erste und einzige Medikament mit positiven Phase-3-Ergebnissen bei Prurigo nodularis, was den potenziellen Nutzen einer gezielten Behandlung von IL-4 und IL-13, zentralen Treibern von Typ-2-Entzündungen, zur Behandlung von Juckreiz und Hautläsionen bestätigt Die Daten bestätigen die Ergebnisse … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged anhaltender Juckreiz, asthma, Atemwegserkrankungen, atopische Dermatitis, dermatologische Erkrankungen, dupilumab, Dupixent, entzündliche Hauterkrankung, extremer Juckreiz, George D. Yancopoulos, Hauterkrankungen, Hautläsionen, Knötchen, Naimish Patel, prurigo nodularis, Regeneron, unerträglicher Juckreiz
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged asthma, atopic dermatitis, CRSwNP, dermatological diseases, dupilumab, Dupixent, extreme itch, George D. Yancopoulos, inflammatory skin disease, Naimish Patel, nodules, persistent itch, prurigo nodularis, Regeneron, respiratory diseases, skin diseases, skin lesions, unbearable itch
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?